Macrovascular disease and systemic sclerosis

Meilien Ho, Douglas Veale, Clifford Eastmond, George Nuki, Jill Belch, for the East of Scotland Systemic Sclerosis Study Group

Abstract
Objective—To determine if macrovascular disease is more prevalent in systemic sclerosis (SSc) compared with unaffected subjects.
Methods—54 patients with SSc (both limited and diffuse disease) and 43 unaffected control subjects of similar age and sex were recruited. All subjects underwent a basic screen for conventional atherosclerotic disease risk factors. All had non-invasive vascular assessments—that is, carotid duplex scanning and measurement of ankle brachial blood pressure index—to identify the presence of asymptomatic peripheral vascular disease.
Results—33 of 52 (64%) patients had carotid artery disease compared with only 15 of 42 (35%) controls (p=0.007). Eleven (21%) of these patients had moderate disease compared with only two (5%) controls (NS). Nine of 53 (17%) SSc patients had evidence of peripheral arterial disease compared with no controls. This result was also statistically significant (p=0.003). There were no significant differences in the basic risk factor profile, which included cigarette smoking, systolic and diastolic blood pressure, cholesterol, triglyceride and glucose concentrations.
Conclusion—Macrovascular disease is more common in SSc. Screening of these patients may allow identification of “at risk” patients at an early stage and allow the study of treatments to attenuate the high rate of cardiovascular mortality in these patients.

Systemic sclerosis (SSc) is a multisystem disorder in which Raynaud’s phenomenon and microcirculatory abnormalities are well recognised. Characteristic features include endothelial dysfunction and haemorrhagological abnormalities. Interestingly, similar abnormalities are seen in patients with macrovascular disease secondary to atherosclerosis. If these changes are pathogenic then you might expect to see atherosclerosis in SSc.

A recently reported inception cohort study demonstrated a fourfold increase in mortality rate (using standardised mortality ratio, SMR) in patients with SSc compared with their unaffected counterparts. Twenty nine per cent of deaths were attributable to cardiovascular causes. We have previously reported a pilot study of SSc patients, which demonstrated a 22% prevalence of symptomatic peripheral arterial obstructive disease (PAOD) as evidenced by the presence of intermittent claudication detected by the Edinburgh Claudication questionnaire, which is a well validated questionnaire. This was almost five times greater than the 4.5% prevalence of symptomatic PAOD seen in the general population, as detected by the WHO claudication questionnaire, which is similar to the Edinburgh questionnaire. A study by Stafford et al identified excess ulnar artery disease also in SSc. If premature atherosclerosis is a feature of SSc, this would have significant implications in terms of patient treatment as it may contribute to their premature mortality. Macrovascular disease however, is not currently recognised as a feature of SSc despite its significant contribution to mortality. The aim of our study was therefore to identify the prevalence of macrovascular disease in SSc by objective laboratory testing.

Methods
PATIENTS
Fifty four consecutive patients fulfilling the 1980 American Rheumatology Association (ARA) criteria for SSc (diffuse cutaneous and limited cutaneous disease) were recruited from our connective tissue disease clinics. The patient pool from which these consecutive patients were taken contains the majority of the known SSc patients in the area and is unselected for vascular or any other complications. Forty three unselected controls of similar age, sex and postal code (for area of residence) were also recruited. They were also unselected for vascular or any other complications. These controls were derived from the general population in the area who were registered with their general practitioners. Any patients or controls with evidence of another connective tissue disease or rheumatoid arthritis (which may also be associated with cardiovascular disease) as shown by a positive antibody to extractable nuclear antigens (ENA) or DNA binding antibody or rheumatoid factor (RF) were excluded. Anti Scl-70 and anti-centromere antibodies were of course acceptable for SSc patients. Any patients with symptoms of Raynaud’s phenomenon were excluded from being a control subject. None of the patients was receiving either intermittent or regular corticosteroid treatment nor had any significant previous history of corticosteroid treatment.

Approval for the study was obtained from the Regional Committees on Medical Research Ethics, and written, informed consent was obtained from all subjects.

BLOOD TESTS
All subjects were screened for conventional atherosclerotic risk factors, which included...
measurement of random blood cholesterol, high density lipoprotein (HDL), triglyceride and glucose concentrations. A smoking history was obtained and blood pressure was also measured. The claudication questionnaire was not included in this paper, which reports on the laboratory findings of large vessel disease, which may be asymptomatic.

**NON-INVASIVE VASCULAR ASSESSMENTS**

Carotid duplex scanning and ankle brachial pressure measurements (ABPI) as measures of peripheral arterial disease, were performed on all subjects. Carotid duplex scanning (Toshiba Powervision with a 7.5 Mhz linear probe) was performed by a vascular technician. Both common, internal and external carotid and vertebral arteries were examined for evidence of stenosis and plaque in the standard manner using a combination of B-mode ultrasound and pulsed colour Doppler signals with audio and spectral analysis. The scans were recorded on video and later assessed by a single, experienced, blind operator. Abnormalities were recorded according to the severity of stenosis—that is, normal, minimal disease (<20% lumen stenosis), moderate (20–49%), severe (50–69%) and critical disease (≥70%). Carotid plaque was classified morphologically according to B-mode appearance and based on the degree of echolucency—that is, Types I–V.12

After a 10 minute rest in a comfortably warm room, bilateral ankle and brachial arterial systolic pressures were measured using a portable Sonicaid Doppler probe and Hawkley random zero sphygmomanometer. The ABPI was calculated as the posterior tibial artery pressure in mm Hg divided by the brachial pressure, and this was done at a later date, during the analysis of the data. The normal ABPI is 1.0, and any value <1.0 is considered to be abnormal13 with the severity of the arterial disease being inversely proportional to the ABPI.14

We selected a definitive ABPI cut off point of 0.9 because this criterion has a 95% sensitivity and 100% specificity for detecting arterial disease using angiographically defined disease as the gold standard14 15 but also evaluated the presence of milder disease with ABPI of <1.0, and <0.98.

**STATISTICS**

The numbers selected were calculated to enable identification of a 15% difference between patients and controls with 90% power at the 5% significance level. Macrovascular disease data were analysed with Fisher's exact test or χ² test as appropriate. Risk factors were analysed and compared using two tailed Student’s t test, and a p value ≤ 0.05 was taken to be statistically significant. Correlations were calculated using Pearson’s correlation coefficient.

**Results**

Demographic details for the 54 SSc patients (13 diffuse:41 limited cutaneous) and 43 controls were similar, with no statistically significant difference between the two groups (table 1). Female:male was 50:4 for patients and 35:8 for controls.

There were no significant differences seen in the risk factors measured between patients and controls (table 1) including smoking status, mean serum cholesterol, HDL, triglyceride and glucose concentrations, and systolic and diastolic blood pressures. Similar numbers of patients and controls had an increased cholesterol of > 5.2 mmol/l (as defined by the National Cholesterol Education Program16). Only two patients and one control subject had an increased random glucose (> 7.8 mmol/l as defined by our laboratory’s own normal range), a marker for a possible underlying diabetic state. Four patients and one control subject had a history of hypertension.

Two patients and one control did not attend for carotid scanning. Thirty three (64%) patients had evidence of carotid disease compared with 15 (35%) controls (p = 0.007, χ² test) (fig 1). When the carotid disease was analysed according to severity, a similar trend was seen for mild disease in 22 (42%) patients and 13 (30%) controls and also for moderate disease, with 11 (21%) patients and two (5%) controls being affected, but neither of these results was not statistically significant. Carotid plaque was present in five patients (Type IV) and three controls (Type I in one control and Type III in two controls).

One patient did not have ABPI measurements. Nine (17%) patients had an ABPI < 0.9 compared with no (0%) control subjects (p = 0.003, Fisher’s test). Twenty (38%) patients and four (10%) control subjects had an ABPI < 0.98 (p=0.002, Fisher’s test) and 21 (40%) patients had an ABPI <1.0 compared with four (10%) controls (p=0.003, Fisher’s test) (fig 1). All subjects—that is, patients and controls with evidence of carotid artery disease—were evaluated independently for the presence of risk factors (table 2). The results showed that affected patients and affected controls were of similar age, with no statistically significant differences in mean serum cholesterol, HDL, triglyceride and glucose concentrations, or mean systolic or diastolic blood pressures. Two of these patients and no control subject with carotid disease were known hypertensives.

Patients with ABPI < 0.9 had a median (range) age of 69 years (52–79) and a median (range) disease duration of 4.4 (1–10) years. They had a cholesterol mean (SD) of 5.5 (1.3) mmol/l; HDL % of 24.9 (6.6); triglyceride

---

**Table 1 Demographic details and risk factor profile**

<table>
<thead>
<tr>
<th></th>
<th>Patients</th>
<th>Controls</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female : male</td>
<td>50:4 (54)</td>
<td>35:8 (43)</td>
<td></td>
</tr>
<tr>
<td>Age (median/range) (y)</td>
<td>57 (31–82)</td>
<td>53 (30–77)</td>
<td>NS</td>
</tr>
<tr>
<td>Diastolic BP mean (SD) mm Hg</td>
<td>79 (18)</td>
<td>77 (18)</td>
<td>NS</td>
</tr>
<tr>
<td>Systolic BP mean (SD) mm Hg</td>
<td>144 (26)</td>
<td>141 (21)</td>
<td>NS</td>
</tr>
<tr>
<td>Number of patients with glucose &gt;7.8 mmol/l†</td>
<td>2 (4%)</td>
<td>1 (3%)</td>
<td>NS</td>
</tr>
<tr>
<td>Triglycerides mean (SD) mmol/l†</td>
<td>1.6 (0.6)</td>
<td>1.5 (0.9)</td>
<td>NS</td>
</tr>
<tr>
<td>HDL mean (SD) %†</td>
<td>27.3 (8.5)</td>
<td>26.3 (9.4)</td>
<td>NS</td>
</tr>
<tr>
<td>Number of patients with cholesterol &gt;5.2 mmol/l†</td>
<td>26 (50%)</td>
<td>18 (48%)</td>
<td>NS</td>
</tr>
<tr>
<td>Cholesterol mean (SD) mmol/l†</td>
<td>5.0 (0.9)</td>
<td>5.1 (1.0)</td>
<td>NS</td>
</tr>
<tr>
<td>Number of smoker</td>
<td>12 (22%)</td>
<td>11 (26%)</td>
<td>NS</td>
</tr>
<tr>
<td>Smoking</td>
<td>12 (22%)</td>
<td>11 (26%)</td>
<td>NS</td>
</tr>
<tr>
<td>Type III in two controls).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (median/range) (y)</td>
<td>57 (31–82)</td>
<td>53 (30–77)</td>
<td>NS</td>
</tr>
<tr>
<td>Female : male</td>
<td>50:4 (54)</td>
<td>35:8 (43)</td>
<td></td>
</tr>
<tr>
<td>Age (median/range) (y)</td>
<td>57 (31–82)</td>
<td>53 (30–77)</td>
<td>NS</td>
</tr>
<tr>
<td>Diastolic BP mean (SD) mm Hg</td>
<td>79 (18)</td>
<td>77 (18)</td>
<td>NS</td>
</tr>
<tr>
<td>Systolic BP mean (SD) mm Hg</td>
<td>144 (26)</td>
<td>141 (21)</td>
<td>NS</td>
</tr>
<tr>
<td>Number of patients with glucose &gt;7.8 mmol/l†</td>
<td>2 (4%)</td>
<td>1 (3%)</td>
<td>NS</td>
</tr>
<tr>
<td>Triglycerides mean (SD) mmol/l†</td>
<td>1.6 (0.6)</td>
<td>1.5 (0.9)</td>
<td>NS</td>
</tr>
<tr>
<td>HDL mean (SD) %†</td>
<td>27.3 (8.5)</td>
<td>26.3 (9.4)</td>
<td>NS</td>
</tr>
<tr>
<td>Number of patients with cholesterol &gt;5.2 mmol/l†</td>
<td>26 (50%)</td>
<td>18 (48%)</td>
<td>NS</td>
</tr>
<tr>
<td>Cholesterol mean (SD) mmol/l†</td>
<td>5.0 (0.9)</td>
<td>5.1 (1.0)</td>
<td>NS</td>
</tr>
<tr>
<td>Number of smoker</td>
<td>12 (22%)</td>
<td>11 (26%)</td>
<td>NS</td>
</tr>
<tr>
<td>Smoking</td>
<td>12 (22%)</td>
<td>11 (26%)</td>
<td>NS</td>
</tr>
</tbody>
</table>
mean (SD) of 1.7 (0.6) and glucose mean (SD) of 5.4 (1.9). Mean systolic and diastolic blood pressures were 156 (26)/85(7) mm Hg. One patient had a history of hypertension. There were no controls with an ABPI < 0.9.

History taking showed that three patients had a history of peripheral arterial disease and three a history of cerebrovascular disease while no controls had a history of peripheral arterial disease or cerebrovascular disease. There was no correlation between macrovascular disease and disease duration or SSc subset (Pearson’s correlation coefficient).

Discussion

Our results show, for the first time by standard laboratory testing, that patients with SSc have an increased prevalence of macrovascular disease in the form of carotid artery disease and PAOD. In this study, carotid disease has been assessed in the same way as for atherosclerotic carotid disease and findings include the detection of plaques characteristically seen in conventional atherosclerotic disease, as well as vessel stenoses. The role of duplex scanning in the investigation of carotid artery disease is well established, and there is evidence to suggest that it has a predictive role in identifying those patients with a greater than normal risk of stroke. Our patients seem to have more severe, as well as more frequent, carotid disease, and such duplex findings suggest that these SSc patients may have an increased risk of a stroke. There is however, no scientific evidence at present to indicate an excessive occurrence of stroke disease in these patients. Our findings, using well validated techniques, contrast with that of a previous study showing no excess of carotid or lower limb arterial disease in SSc. There were, however, only 20 patients in this study, which also used a different methodology for measurement of intraluminal diameter and limited the examination to specific sites.

Figure 1 Prevalence of carotid and peripheral arterial disease in SSc patients compared with controls.

Table 2 Risk factor profile* of all subjects with carotid artery disease

<table>
<thead>
<tr>
<th></th>
<th>Patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number (%)</td>
<td>33 (64)</td>
<td>15 (35)</td>
</tr>
<tr>
<td>Age median (range) (y)</td>
<td>61 (37–82)</td>
<td>60 (45–77)</td>
</tr>
<tr>
<td>Cholesterol mean (SD) mmol/l</td>
<td>5.1 (1.0)</td>
<td>5.3 (1.3)</td>
</tr>
<tr>
<td>HDL mean (SD) %</td>
<td>27.3 (8.9)</td>
<td>25.4 (9.4)</td>
</tr>
<tr>
<td>Triglyceride mean (SD) mmol/l</td>
<td>1.5 (0.7)</td>
<td>1.7 (1.2)</td>
</tr>
<tr>
<td>Glucose mean (SD) mmol/l</td>
<td>5.2 (1.3)</td>
<td>5.4 (1.2)</td>
</tr>
<tr>
<td>Systolic BP mean (SD) mm Hg</td>
<td>148 (27)</td>
<td>148 (18)</td>
</tr>
<tr>
<td>Diastolic BP mean (SD) mm Hg</td>
<td>77 (19)</td>
<td>84 (9)</td>
</tr>
</tbody>
</table>

*Not statistically significant.
discussion. We recognise that the usual method is to select alphabetically matched controls from general practice lists but felt it would be more appropriate to match the subjects for social class as social habits and behaviour are important factors in cardiovascular morbidity and mortality. Thus we selected age and sex matched controls with matching for postcode areas.

There are similarities in clinical symptomatology between SSc and atherosclerotic disease with digital and lower limb ulcers occurring in both clinical scenario. Further similarities are seen in the histopathology of the affected vessels and the aetiopathogenesis of both diseases. The question therefore, is whether this macrovascular disease of SSc is atherosclerotic in nature: this remains unanswered at present.

Nevertheless, this finding has important clinical implications and targeted treatment may be indicated in high risk patients. PAOD itself is associated with increased cardiovascular mortality. The degree of lowering of the ABPI is correlated to the severity of disease; disease severity is, in turn, directly correlated with an increasing risk of both fatal and non-fatal cardiovascular events at all levels of a reduced ABPI from < 0.7 up to 1.0. In women, an ABPI < 0.9 confers a 2.1 (95% CI 1.4, 3.1) relative risk of cardiovascular mortality and with an ABPI < 0.85, the relative risk for cardiovascular events is 4.0 (1.3, 8.5). SSc is also associated with a higher rate of cardiovascular mortality compared with unaffected persons. This is not universally appreciated; mortality studies generally classify deaths as being either related to or unrelated to SSc and many cardiovascular deaths are automatically (but incorrectly we believe) assumed to be unrelated to SSc and categorised as a non-SSc related death. Support for this belief comes from a recent study, which showed that SSc patients experienced twice the expected number of non-SSc related deaths, the majority of which were cardiovascular in nature. The overall pattern of increased large vessel disease associated with cardiovascular events mirrors that of atherosclerotic disease. Large studies have shown a significant decrease in cardiovascular events in patients with atherosclerotic peripheral arterial disease treated with aspirin and other antiplatelet agents. Aspirin however may be more appropriate to match the subjects for social class as social habits and behaviour are important factors in cardiovascular morbidity and mortality. Thus we selected age and sex matched controls with matching for postcode areas.

Support for this belief comes from a recent study categorised as a non-SSc related death. Further work is required in this area to elucidate the nature of the macrovascular abnormalities and the risk factors associated with it, which may well be amenable to treatment and allow attenuation of the high rate of cardiovascular deaths in this group of patients.

Funding: this study was funded by the Raynaud's and Scleroderma Association, UK. The duplex scanning equipment was purchased through a grant from the Medical Research Council.


Downloaded from http://ard.bmj.com/ on June 25, 2017 - Published by group.bmj.com
Macrovascular disease and systemic sclerosis

Meilien Ho, Douglas Veale, Clifford Eastmond, George Nuki and Jill Belch

doi: 10.1136/ard.59.1.39

Updated information and services can be found at:
http://ard.bmj.com/content/59/1/39

These include:

References
This article cites 29 articles, 13 of which you can access for free at:
http://ard.bmj.com/content/59/1/39#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Connective tissue disease (4253)
Epidemiology (1367)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/